-
1
-
-
33846462456
-
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
-
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 348-359
-
-
Cornely, O.A.1
Maertens, J.2
Winston, D.J.3
Perfect, J.4
Ullmann, A.J.5
Walsh, T.J.6
Helfgott, D.7
Holowiecki, J.8
Stockelberg, D.9
Goh, Y.-T.10
Petrini, M.11
Hardalo, C.12
Suresh, R.13
Angulo-Gonzalez, D.14
-
2
-
-
33845710284
-
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
-
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik J-AH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086/508774.
-
(2007)
Clin. Infect. Dis.
, vol.44
, pp. 2-12
-
-
Walsh, T.J.1
Raad, I.2
Patterson, T.F.3
Chandrasekar, P.4
Donowitz, G.R.5
Graybill, R.6
Greene, R.E.7
Hachem, R.8
Hadley, S.9
Herbrecht, R.10
Langston, A.11
Louie, A.12
Ribaud, P.13
Segal, B.H.14
Stevens, D.A.15
Van Burik, J.-A.H.16
White, C.S.17
Corcoran, G.18
Gogate, J.19
Krishna, G.20
Pedicone, L.21
Hardalo, C.22
Perfect, J.R.23
more..
-
3
-
-
13244268757
-
Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations
-
Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220. http://dx.doi.org/10.2165/00003088-200544020-00006.
-
(2005)
Clin. Pharmacokinet.
, vol.44
, pp. 211-220
-
-
Ezzet, F.1
Wexler, D.2
Courtney, R.3
Krishna, G.4
Lim, J.5
Laughlin, M.6
-
4
-
-
62949244126
-
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers
-
Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 958-966
-
-
Krishna, G.1
Moton, A.2
Ma, L.3
Medlock, M.M.4
McLeod, J.5
-
5
-
-
80053609420
-
Effect of pH and comedication on gastrointestinal absorption of posaconazole
-
Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. 2011. Effect of pH and comedication on gastrointestinal absorption of posaconazole. Clin. Pharmacokinet. 50:725-734. http://dx.doi.org/10.2165/11592630-000000000-00000.
-
(2011)
Clin. Pharmacokinet.
, vol.50
, pp. 725-734
-
-
Walravens, J.1
Brouwers, J.2
Spriet, I.3
Tack, J.4
Annaert, P.5
Augustijns, P.6
-
6
-
-
84868033749
-
Multicenter study of posaconazole therapeutic drug monitoring: Exposure-response relationship and factors affecting concentration
-
Dolton MJ, Ray JE, Chen SCA, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.00802-12.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 5503-5510
-
-
Dolton, M.J.1
Ray, J.E.2
Chen, S.C.A.3
Ng, K.4
Pont, L.5
McLachlan, A.J.6
-
7
-
-
80051792869
-
Posaconazole plasma concentrations in critically ill patients
-
Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. 2011. Posaconazole plasma concentrations in critically ill patients. Ther. Drug Monit. 33:387-392. http://dx.doi.org/10.1097/FTD.0b013e31821fb197.
-
(2011)
Ther. Drug Monit.
, vol.33
, pp. 387-392
-
-
Ray, J.1
Campbell, L.2
Rudham, S.3
Nguyen, Q.4
Marriott, D.5
-
8
-
-
65549159077
-
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents
-
Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM, Saravolatz LD. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458. http://dx.doi.org/10.1086/598327.
-
(2009)
Clin. Infect. Dis.
, vol.48
, pp. 1441-1458
-
-
Brüggemann, R.J.M.1
Alffenaar, J.-W.C.2
Blijlevens, N.M.A.3
Billaud, E.M.4
Kosterink, J.G.W.5
Verweij, P.E.6
Burger, D.M.7
Saravolatz, L.D.8
-
9
-
-
84861116449
-
Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring
-
Dolton MJ, Ray JE, Marriott D, Mclachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx.doi.org/10.1128/AAC.05900-11.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 2806-2813
-
-
Dolton, M.J.1
Ray, J.E.2
Marriott, D.3
Mclachlan, A.J.4
-
10
-
-
33846410666
-
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
-
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10.1056/NEJMoa061098.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 335-347
-
-
Ullmann, A.J.1
Lipton, J.H.2
Vesole, D.H.3
Chandrasekar, P.4
Langston, A.5
Tarantolo, S.R.6
Greinix, H.7
De Morais Azevedo, W.8
Reddy, V.9
Boparai, N.10
Pedicone, L.11
Patino, H.12
Durrant, S.13
-
11
-
-
77953809369
-
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on drug concentrations in plasma
-
Jang SH, Colangelo PM, Gobburu JVS. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010.64.
-
(2010)
Clin. Pharmacol. Ther.
, vol.88
, pp. 115-119
-
-
Jang, S.H.1
Colangelo, P.M.2
Gobburu, J.V.S.3
-
12
-
-
79951811382
-
Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections
-
Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352. http://dx.doi.org/10.1038/clpt.2010.261.
-
(2011)
Clin. Pharmacol. Ther.
, vol.89
, pp. 351-352
-
-
Cornely, O.A.1
Ullmann, A.J.2
-
13
-
-
84892534686
-
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
-
Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. 2013. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev. Anti Infect. Ther. 11:931-941. http://dx.doi.org/10.1586/14787210.2013.826989.
-
(2013)
Expert Rev. Anti Infect. Ther.
, vol.11
, pp. 931-941
-
-
Seyedmousavi, S.1
Mouton, J.W.2
Verweij, P.E.3
Brüggemann, R.J.4
-
14
-
-
84861229084
-
Posaconazole treatment in hematology patients: A pilot study of therapeutic drug monitoring
-
Crombag M-RBS, Huisman C, Kemper EM, Brüggemann RJM, Bijleveld YA. 2012. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Ther. Drug Monit. 34:320-325. http://dx.doi.org/10.1097/FTD.0b013e31824d135c.
-
(2012)
Ther. Drug Monit.
, vol.34
, pp. 320-325
-
-
M-Rbs, C.1
Huisman, C.2
Kemper, E.M.3
Brüggemann, R.J.M.4
Bijleveld, Y.A.5
-
15
-
-
75749102569
-
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene
-
Mavridou E, Bruggemann RJM, Melchers WJG, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865. http://dx.doi.org/10.1128/AAC.00931-09.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 860-865
-
-
Mavridou, E.1
Bruggemann, R.J.M.2
Melchers, W.J.G.3
Mouton, J.W.4
Verweij, P.E.5
-
16
-
-
84857058536
-
Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: Influence of food intake
-
Eiden C, Meniane JC, Peyrière H, Eymard-Duvernay S, Le Falher G, Ceballos P, Fegueux N, Cociglio M, Reynes J, Hillaire-Buys D. 2011. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur. J. Clin. Microbiol. Infect. Dis. 31:161-167. http://dx.doi.org/10.1007/s10096-011-1288-9.
-
(2011)
Eur. J. Clin. Microbiol. Infect. Dis.
, vol.31
, pp. 161-167
-
-
Eiden, C.1
Meniane, J.C.2
Peyrière, H.3
Eymard-Duvernay, S.4
Le Falher, G.5
Ceballos, P.6
Fegueux, N.7
Cociglio, M.8
Reynes, J.9
Hillaire-Buys, D.10
-
17
-
-
84860477358
-
Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies
-
Hoenigl M, Raggam RB, Salzer HJF, Valentin T, Valentin A, Zollner-Schwetz I, Strohmeier AT, Seeber K, Wölfler A, Sill H, Krause R. 2012. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int. J. Antimicrob. Agents 39:510-513. http://dx.doi.org/10.1016/j.ijantimicag.2012.02.002.
-
(2012)
Int. J. Antimicrob. Agents
, vol.39
, pp. 510-513
-
-
Hoenigl, M.1
Raggam, R.B.2
Salzer, H.J.F.3
Valentin, T.4
Valentin, A.5
Zollner-Schwetz, I.6
Strohmeier, A.T.7
Seeber, K.8
Wölfler, A.9
Sill, H.10
Krause, R.11
-
18
-
-
66149083562
-
Posaconazole therapeutic drug monitoring: A reference laboratory experience
-
Thompson GR, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224. http://dx.doi.org/10.1128/AAC.00240-09.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 2223-2224
-
-
Thompson, G.R.1
Rinaldi, M.G.2
Pennick, G.3
Dorsey, S.A.4
Patterson, T.F.5
Lewis, J.S.6
-
19
-
-
79951949693
-
A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis
-
Bryant AM, Slain D, Cumpston A, Craig M. 2011. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int. J. Antimicrob. Agents 37:266-269. http://dx.doi.org/10.1016/j.ijantimicag.2010.11.021.
-
(2011)
Int. J. Antimicrob. Agents
, vol.37
, pp. 266-269
-
-
Bryant, A.M.1
Slain, D.2
Cumpston, A.3
Craig, M.4
-
20
-
-
84908304514
-
-
revised 11/2013 fda-docs/label/2013/205053s000lbl.pdf Accessed 3 March 2014
-
Merck Inc. 2014. Noxafil prescribing information, revised 11/2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205053s000lbl.pdf. Accessed 3 March 2014.
-
(2014)
Noxafil Prescribing Information
-
-
-
21
-
-
77957226579
-
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers
-
Brüggemann RJM, Van Luin M, Colbers EPH, van den Dungen MW, Pharo C, Schouwenberg BJJW, Burger DM. 2010. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J. Antimicrob. Chemother. 65:2188-2194. http://dx.doi.org/10.1093/jac/dkq280.
-
(2010)
J. Antimicrob. Chemother.
, vol.65
, pp. 2188-2194
-
-
Brüggemann, R.J.M.1
Van Luin, M.2
Colbers, E.P.H.3
Van Den Dungen, M.W.4
Pharo, C.5
Bjjw, S.6
Burger, D.M.7
-
22
-
-
84865470874
-
Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model)
-
Shen J, Boeckmann A, Vick A. 2012. Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J. Pharmacokinet. Pharmacodyn. 39:251-262. http://dx.doi.org/10.1007/s10928-012-9247-3.
-
(2012)
J. Pharmacokinet. Pharmacodyn.
, vol.39
, pp. 251-262
-
-
Shen, J.1
Boeckmann, A.2
Vick, A.3
-
23
-
-
79957451960
-
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models
-
Bergstrand M, Hooker A, Wallin J, Karlsson M. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.AAPS J. 13:143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
-
(2011)
AAPS J.
, vol.13
, pp. 143-151
-
-
Bergstrand, M.1
Hooker, A.2
Wallin, J.3
Karlsson, M.4
-
24
-
-
74549125472
-
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
-
AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26:397-405. http://dx.doi.org/10.1185/03007990903485056.
-
(2010)
Curr. Med. Res. Opin.
, vol.26
, pp. 397-405
-
-
AbuTarif, M.A.1
Krishna, G.2
Statkevich, P.3
-
25
-
-
73849110835
-
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
-
Kohl V, Müller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJGT. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212. http://dx.doi.org/10.1128/AAC.01027-09.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 207-212
-
-
Kohl, V.1
Müller, C.2
Cornely, O.A.3
Abduljalil, K.4
Fuhr, U.5
Vehreschild, J.J.6
Scheid, C.7
Hallek, M.8
Rüping, M.J.G.T.9
-
26
-
-
84864286296
-
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
-
Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V. 2012. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur. J. Clin. Pharmacol. 68:987-995. http://dx.doi.org/10.1007/s00228-012-1212-y.
-
(2012)
Eur. J. Clin. Pharmacol.
, vol.68
, pp. 987-995
-
-
Vehreschild, J.J.1
Müller, C.2
Farowski, F.3
Vehreschild, M.J.4
Cornely, O.A.5
Fuhr, U.6
Kreuzer, K.A.7
Hallek, M.8
Kohl, V.9
-
27
-
-
85010936123
-
-
London, United Kingdom Accessed 1 November 2013
-
European Medicines Agency. 2005. Noxafil: EPAR - scientific discussion. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000610/WC500037781.pdf. Accessed 1 November 2013.
-
(2005)
Noxafil: EPAR - Scientific Discussion
-
-
-
28
-
-
70350326279
-
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers
-
Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752. http://dx.doi.org/10.1128/AAC.00889-09.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 4749-4752
-
-
Krishna, G.1
Ma, L.2
Vickery, D.3
Yu, X.4
Wu, I.5
Power, E.6
Beresford, E.7
Komjathy, S.8
-
29
-
-
54749151049
-
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
-
Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.
-
(2008)
Pharmacotherapy
, vol.28
, pp. 1223-1232
-
-
Krishna, G.1
AbuTarif, M.2
Xuan, F.3
Martinho, M.4
Angulo, D.5
Cornely, O.A.6
-
30
-
-
36849064207
-
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease
-
Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627.
-
(2007)
Pharmacotherapy
, vol.27
, pp. 1627-1636
-
-
Krishna, G.1
Martinho, M.2
Chandrasekar, P.3
Ullmann, A.J.4
Patino, H.5
-
31
-
-
84860117262
-
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
-
Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJGT, Krishna G, Ma L, Huyck S, McCarthy MC. 2012. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob. Agents Chemother. 56:2652-2658. http://dx.doi.org/10.1128/AAC.05937-11.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 2652-2658
-
-
Cornely, O.A.1
Helfgott, D.2
Langston, A.3
Heinz, W.4
Vehreschild, J.J.5
Vehreschild, M.J.G.T.6
Krishna, G.7
Ma, L.8
Huyck, S.9
McCarthy, M.C.10
-
32
-
-
71249114710
-
Therapeutic drug monitoring of posaconazole: A monocentric study with 54 adults
-
Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard J-P, Bougnoux M-E, Lecuit M, Jullien V, Lortholary O. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob. Agents Chemother. 53:5224-5229. http://dx.doi.org/10.1128/AAC.00939-09.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 5224-5229
-
-
Lebeaux, D.1
Lanternier, F.2
Elie, C.3
Suarez, F.4
Buzyn, A.5
Viard, J.-P.6
Bougnoux, M.-E.7
Lecuit, M.8
Jullien, V.9
Lortholary, O.10
-
33
-
-
34347211017
-
Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men
-
Krishna G, Sansone-Parsons A, Kantesaria B. 2007. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr. Med. Res. Opin. 23:1415-1422. http://dx.doi.org/10.1185/030079907X187937.
-
(2007)
Curr. Med. Res. Opin.
, vol.23
, pp. 1415-1422
-
-
Krishna, G.1
Sansone-Parsons, A.2
Kantesaria, B.3
-
34
-
-
33947354866
-
Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men
-
Krishna G, Parsons A, Kantesaria B, Mant T. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr. Med. Res. Opin. 23:545-552. http://dx.doi.org/10.1185/030079906X167507.
-
(2007)
Curr. Med. Res. Opin.
, vol.23
, pp. 545-552
-
-
Krishna, G.1
Parsons, A.2
Kantesaria, B.3
Mant, T.4
-
35
-
-
77749277056
-
Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations
-
Hohmann C, Kang EM, Jancel T. 2010. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin. Infect. Dis. 50:939-940. http://dx.doi.org/10.1086/650740.
-
(2010)
Clin. Infect. Dis.
, vol.50
, pp. 939-940
-
-
Hohmann, C.1
Kang, E.M.2
Jancel, T.3
-
36
-
-
77956593204
-
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: An overview
-
Lipp H-P. 2010. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br. J. Clin. Pharmacol. 70:471-480. http://dx.doi.org/10.1111/j.1365-2125.2010.03680.x.
-
(2010)
Br. J. Clin. Pharmacol.
, vol.70
, pp. 471-480
-
-
Lipp, H.-P.1
-
37
-
-
0842304211
-
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)
-
Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, Zbaida S. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. 32:267-271. http://dx.doi.org/10.1124/dmd.32.2.267.
-
(2004)
Drug Metab. Dispos.
, vol.32
, pp. 267-271
-
-
Ghosal, A.1
Hapangama, N.2
Yuan, Y.3
Achanfuo-Yeboah, J.4
Iannucci, R.5
Chowdhury, S.6
Alton, K.7
Patrick, J.E.8
Zbaida, S.9
-
38
-
-
8844262477
-
Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs
-
Anderson GD. 2004. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63(10 Suppl 4):S3-S8. http://dx.doi.org/10.1212/WNL.63.10-suppl-4.S3.
-
(2004)
Neurology
, vol.63
, Issue.10
, pp. S3-S8
-
-
Anderson, G.D.1
-
39
-
-
0029758162
-
Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver
-
Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. 1996. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J. Antimicrob. Chemother. 37:1111-1119. http://dx.doi.org/10.1093/jac/37.6.1111.
-
(1996)
J. Antimicrob. Chemother.
, vol.37
, pp. 1111-1119
-
-
Oesch, F.1
Arand, M.2
Benedetti, M.S.3
Castelli, M.G.4
Dostert, P.5
-
40
-
-
67649975620
-
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers
-
Dodds Ashley ES, Varkey JB, Krishna G, Vickery D, Ma L, Yu X, Malavade D, Goodwin M, Perfect JR, Power E. 2009. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob. Agents Chemother. 53:2960-2964. http://dx.doi.org/10.1128/AAC.01178-08.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 2960-2964
-
-
Dodds Ashley, E.S.1
Varkey, J.B.2
Krishna, G.3
Vickery, D.4
Ma, L.5
Yu, X.6
Malavade, D.7
Goodwin, M.8
Perfect, J.R.9
Power, E.10
-
41
-
-
84864383906
-
Plasma concentrations of posaconazole administered via nasogastric tube in patients of a surgical intensive care unit
-
Störzinger D, Borghorst S, Hofer S, Busch CJ, Lichtenstern C, Hempel G, Weigand MA, Hoppe-Tichy T. 2012. Plasma concentrations of posaconazole administered via nasogastric tube in patients of a surgical intensive care unit. Antimicrob. Agents Chemother. 56:4468-4470. http://dx.doi.org/10.1128/AAC.06167-11.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 4468-4470
-
-
Störzinger, D.1
Borghorst, S.2
Hofer, S.3
Busch, C.J.4
Lichtenstern, C.5
Hempel, G.6
Weigand, M.A.7
Hoppe-Tichy, T.8
-
42
-
-
84898452706
-
Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology
-
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
-
(2014)
J. Antimicrob. Chemother.
, vol.69
, pp. 1162-1176
-
-
Ashbee, H.R.1
Barnes, R.A.2
Johnson, E.M.3
Richardson, M.D.4
Gorton, R.5
Hope, W.W.6
-
43
-
-
84903899191
-
Understanding variability with voriconazole using a population pharmacokinetic approach: Implications for optimal dosing
-
Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ. 2014. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J. Antimicrob. Chemother. 69:1633-1641. http://dx.doi.org/10.1093/jac/dku031.
-
(2014)
J. Antimicrob. Chemother.
, vol.69
, pp. 1633-1641
-
-
Dolton, M.J.1
Mikus, G.2
Weiss, J.3
Ray, J.E.4
McLachlan, A.J.5
-
44
-
-
31944443967
-
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
-
Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. http://dx.doi.org/10.1128/AAC.50.2.658-666.2006.
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, pp. 658-666
-
-
Ullmann, A.J.1
Cornely, O.A.2
Burchardt, A.3
Hachem, R.4
Kontoyiannis, D.P.5
Töpelt, K.6
Courtney, R.7
Wexler, D.8
Krishna, G.9
Martinho, M.10
Corcoran, G.11
Raad, I.12
|